Potential therapy derived from a banana protein works against SARS-CoV-2

The antiviral is also effective against all known coronaviruses and influenza.

12:28 PM

Author | Kelly Malcom

banana fingers going in pill bottle animated blue orange
Justine Ross, Michigan Medicine

On January 13, 2020, a paper touting the creation of a possible therapy that could be used to fight all known strains of the flu was published online.

One week later, the first laboratory confirmed case of SARS-CoV-2 set off the two and a half year-long COVID-19 pandemic in the United States.

Interestingly, prior to the arrival of the virus that temporarily shut down their work, the international study team behind the influenza paper had also investigated these banana-derived therapies for coronaviruses.

"At the time we thought MERS would be the big target, which we were worried about because of its 35% mortality rate," said David Markovitz, M.D., professor of internal medicine, Division of Infectious Diseases at the University of Michigan Medical School. (MERS, or Middle Eastern Respiratory Syndrome, caused a brief outbreak in 2015 and resulted in 858 confirmed deaths.)

A paper in Cell Reports Medicine details the efficacy of H84T-BanLec against all known human-infecting coronaviruses, including MERS, the original SARS, and SARS-CoV-2, including the Omicron variant. Markovitz is joined by two senior authors, Peter Hinterdorfer, Ph.D., of the Johannes Kepler University Institute of Biophysics and Kwok-Yung Yuen, MBBS, M.D., of the University of Hong Kong. The first author on the paper is Jasper Fuk-Woo Chan, M.D., of the University of Hong Kong.

"When COVID-19 occurred, we of course wanted to study the therapy's potential and discovered it was effective against every type of coronavirus, in vitro and in vivo," Markovitz said. "Whether delivered systemically or through the nose in animal models, or prophylactically or therapeutically early on in the illness, it worked."

H84T-BanLec is derived from a lectin (a carbohydrate-binding protein) isolated from banana fruit. It accomplishes its remarkable viral-blocking abilities by binding to high-mannose glycans, polysaccharides that are present on the surface of the viruses, but only very rarely on normal healthy human cells. After binding, the virus cannot enter cells to infect them.

Using atomic force microscopy and related methods, the team confirmed that H84T develops multiple strong bonds with the spike protein, which, said Markovitz, probably explains why it's hard for a coronavirus to be resistant to the lectin.

Despite their anti-viral potential, lectins have traditionally been avoided as possible therapies because they are proteins that can stimulate the immune system in a potentially harmful way, explains Markovitz. However, H84T-BanLec has been modified to remove this effect and showed no detrimental effects in the animal models.

While several treatments for COVID-19 currently exist, including remdesivir, Paxlovid and monoclonal antibodies, they have varied levels of effectiveness, side effects and ease of use and many have proven less effective as SARS-CoV-2 continues to evolve.

H84T-BanLec holds unique promise, according to the team, because it is effective against all coronavirus variants as well as influenza viruses. Markovitz and the team hope to see the therapy take the more difficult step from animal models to testing in humans. The team envisions a nasal spray or drops that can be used to prevent or treat coronavirus and influenza infections in seasonal and pandemic situations. They also hope to examine using H84T-BanLec against cancer—as cancer cells, like viruses, also have high mannose glycans on their surfaces.

Additional authors include Yoo Jin Oh, Shuofeng Yuan , Hin Chu , Man-Lung Yeung , Daniel Canena , Chris Chung-Sing Chan, Vincent Kwok-Man Poon, Chris ChunYiu Chan, Anna Jinxia Zhang, Jian-Piao Cai , Zi-Wei Ye , Lei Wen, Terrence Tsz-Tai Yuen, Kenn Ka-Heng Chik, Huiping Shuai, Yixin Wang, Yuxin Hou, Cuiting Luo, WanMui Chan, Zhenzhi Qin, Ko-Yung Sit, Wing-Kuk Au, Maureen Legendre, Rong Zhu, Lisa Hain , Hannah Seferovic, Robert Tampé, Kelvin Kai-Wang To, Kwok-Hung Chan, Dafydd Gareth Thomas, Miriam Klausberger, Cheng Xu , James J. Moon, Johannes Stadlmann, Josef M. Penninger, and Chris Oostenbrink. Thomas, Xu, Moon and Legendre are all from the University of Michigan.

Live your healthiest life: Get tips from top experts weekly. Subscribe to the Michigan Health blog newsletter

Headlines from the frontlines: The power of scientific discovery harnessed and delivered to your inbox every week. Subscribe to the Michigan Health Lab blog newsletter

Like Podcasts? Add the Michigan Medicine News Break on Spotify, Apple Podcasts or anywhere you listen to podcasts.

Paper cited: "A Molecularly Engineered, Broad-spectrum Anti-coronavirus 2 Lectin Inhibits SARS-CoV-2 and MERS-CoV Infection In Vivo," Cell Reports Medicine. DOI: 10.1016/j.xcrm.2022.100774


More Articles About: Lab Report All Research Topics Community Health Future Think Covid-19 Immunizations COVID-19 Vaccine Hospitals & Centers infectious disease
Health Lab word mark overlaying blue cells
Health Lab

Explore a variety of health care news & stories by visiting the Health Lab home page for more articles.

Media Contact Public Relations

Department of Communication at Michigan Medicine

[email protected]

734-764-2220

Stay Informed

Want top health & research news weekly? Sign up for Health Lab’s newsletters today!

Subscribe
Featured News & Stories woman laying on floating cell maroon
Health Lab
Circadian rhythm drives the release of important immune cells
A study shows circadian rhythm drives the release of important immune cells in the body.
person holding arm with band aid teal shirt
Health Lab
More hospitals than ever require staff to get flu shots
Flu vaccination mandates for hospital staff have increased in recent years, especially at hospitals serving veterans
woman smiling with white short hair and earrings dark with orange background
Health Lab
Using biologic injections for severe asthma after COVID
Biologic injections end up being the best treatment for treating severe asthma after having COVID for one patient.
stethoscope blue yellow
Health Lab
New drug could help those with CAH reduce the use of corticosteroids
Michigan Medicine researchers discover that a new drug could help those with CAH, or congenital adrenal hyperplasia, reduce the use of corticosteroids. 
cancer cell blue yellow
Health Lab
Accessibility issues in cancer care
Researchers at the University of Michigan are finding that many patients may be encountering significant barriers to cancer care, even from their first phone call to a clinic.
orange background, blue skull, brain maze inside large brain and person with white coat looking at it with a magnifying glass
Health Lab
Uncovering mysteries of the developing brain
The ABCD study, a long-term study of the brains of thousands of young people from preteen to late teen years, is revealing important insights into behavior and mental health.